Capricor Therapeutics CAPR Net unrealized gains (losses) on securities still held
Net unrealized gains (losses) on securities still held at other companies
Other financials
Where this comes from
Reported directly by Capricor Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax.
The official record: Capricor Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Capricor Therapeutics's net unrealized gains (losses) on securities still held.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Capricor Therapeutics's net unrealized gains (losses) on securities still held?
- Capricor Therapeutics (CAPR) reported net unrealized gains (losses) on securities still held of -$536.88K in Q1 2026.
- How has Capricor Therapeutics's net unrealized gains (losses) on securities still held changed year-over-year?
- Capricor Therapeutics's net unrealized gains (losses) on securities still held decreased by 168.4% year-over-year, from $784.97K to -$536.88K.
- What does net unrealized gains (losses) on securities still held mean?
- This metric represents the change in the fair value of investment securities held by the company that have not yet been sold. It captures fluctuations in the market value of the investment portfolio that are recognized in equity rather than through the income statement. Monitoring this figure helps investors assess the volatility and potential future liquidity impact of the company's non-operating asset holdings.